BioSpace News Archive

O2 Aero Acquisitions, LLC today announced it has acquired Shaw Aerox, LLC (“Aerox”), a leading designer and manufacturer of installed and portable oxygen systems and accessories for aviation and medical users, for an undisclosed amount

The country is carefully navigating through the COVID-19 challenge, and executive orders are being lifted in phases across the country.

The National Organization for Rare Disorders has announced new awards through its Rare Disease Research Grant Program, which provides funding to qualified researchers for translational or clinical studies related to the development of new diagnostics or treatments for rare disease.

Prellis Biologics, Inc. announced that it has generated 300 human IgG antibodies that bind to either the S1 or S2 spike protein of the SARS-CoV2-Wuhan strain of the novel coronavirus.

Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its investigational small-molecule pyruvate kinase M2 isoform

Completes Enrollment of Phase 2 Candida Trial Treats First Patients in Phase 2 Trials in Aspergillus and Candida auris Infections

Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, and NantKwest (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer and infectious diseases,

58% complete response rate reported for patients with relapsed/refractory MCL, with a median follow-up of 8.3 months 100% progression-free survival reported for patients with CLL, with a median follow-up of 12.8 months Cirmtuzumab continued to be well tolerated in this trial SAN DIEGO--( BUSINESS WIRE )-- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel

Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the company will host a live conference call and webcast on Monday, June 8, 2020 at 1:00 pm PDT to report data in healthy volunteers from the

Tyme Technologies, Inc. (NASDAQ:TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that leadership will participate at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020. The Company will present its corporate overview for 2020 with a special focus on multiple growth opportunities driven by advances in the science of cancer metabolism, pivotal trials in